Goklu Mehmet Rıfat, Seckin Kerem Doga, Togrul Cihan, Goklu Yasemin, Tahaoglu Ali Emre, Oz Murat, Ertas Ibrahim Egemen
Obstetrics and Gynecology Department, Diyarbakir Maternity Hospital, Diyarbakir, Turkey E-mail :
Asian Pac J Cancer Prev. 2015;16(10):4219-22. doi: 10.7314/apjcp.2015.16.10.4219.
Hydronephrosis is frequently encountered in advanced stage cervical cancers, and may be associated with mortality. In the present study, we aimed to demonstrate the effect of hydronephrosis on survival in patients with inoperable advanced stage cervical cancer.
The study data were acquired by retrospective analysis of the patient records belonging to 165 women with FIGO (International Federation of Gynecology and Obstetrics) stage-IIIB or more advanced cervical cancer, which were not surgical candidates. Parameters including patient age, pathological diagnosis, disease stage, pelvic sidewall extension, presence of hydronephrosis and administration of chemoradiation were analyzed. Further, the effects of these variables on survival were assessed. P values less than 0.05 were considered statistically significant.
The distribution of the study patients according to disease stage was as follows: 131 (79.4%) had stage-IIIB, 18 (10.9%) had stage-IVB and 16 (% 9.7) patients had stage-IVA disease. Hydronephrosis was not evident in 91 (55.2%) of these patients, whereas 41 (24.8%) had unilateral and 33 (20%) patients had bilateral hydronephrosis. When compared to mean survival in patients who did not have hydronephrosis, survival was significantly shortened in patients who had bilateral and unilateral hydronephrosis (p<0.05). There was no significant survival difference between patients with unilateral and bilateral hydronephrosis (p>0.05). Although patient age, pathological type, pelvic involvement, and chemotherapy treatment rates were similar (p>0.05), radiotherapy requirement rate and disease stage were significantly different among the study groups (p<0.05).
Hydronephrosis was found to be a significant predictor of poor survival in patients with advanced stage cervical cancer, irrespective of unilateral or bilateral involvement.While waiting for future studies with larger sample sizes, we believe that the FIGO stages in advanced cervical cancer could further be stratified into subgroups according to presence or absence of hydronephrosis.
肾积水在晚期宫颈癌中经常出现,并且可能与死亡率相关。在本研究中,我们旨在证明肾积水对无法手术的晚期宫颈癌患者生存的影响。
通过回顾性分析165例国际妇产科联盟(FIGO)IIIB期或更晚期宫颈癌且不适合手术的女性患者的病历获取研究数据。分析了包括患者年龄、病理诊断、疾病分期、盆腔侧壁受累情况、肾积水的存在以及放化疗的应用等参数。此外,评估了这些变量对生存的影响。P值小于0.05被认为具有统计学意义。
研究患者按疾病分期的分布如下:131例(79.4%)为IIIB期,18例(10.9%)为IVB期,16例(9.7%)为IVA期疾病。这些患者中91例(55.2%)未出现明显肾积水,而41例(24.8%)有单侧肾积水,33例(20%)有双侧肾积水。与无肾积水患者的平均生存期相比,有双侧和单侧肾积水的患者生存期显著缩短(p<0.05)。单侧和双侧肾积水患者之间的生存期无显著差异(p>0.05)。尽管患者年龄、病理类型、盆腔受累情况和化疗治疗率相似(p>0.05),但研究组之间放疗需求率和疾病分期存在显著差异(p<0.05)。
发现肾积水是晚期宫颈癌患者生存不良的重要预测因素,无论单侧或双侧受累情况如何。在等待未来更大样本量的研究时,我们认为晚期宫颈癌的FIGO分期可根据肾积水的有无进一步分层为亚组。